ResMed Director Peter Farrell Sells 25,000 Shares (RMD)
ResMed (NYSE:RMD) Director Peter Farrell unloaded 25,000 shares of the company’s stock on the open market in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $53.21, for a total transaction of $1,330,250.00. Following the completion of the transaction, the director now directly owns 507,195 shares in the company, valued at approximately $26,987,846. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
ResMed (NYSE:RMD) traded up 1.20% on Friday, hitting $54.01. The stock had a trading volume of 783,853 shares. ResMed has a 1-year low of $38.08 and a 1-year high of $54.39. The stock has a 50-day moving average of $51.12 and a 200-day moving average of $47.95. The company has a market cap of $7.672 billion and a price-to-earnings ratio of 25.41.
ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.62 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.62. The company had revenue of $414.60 million for the quarter, compared to the consensus estimate of $410.89 million. During the same quarter in the prior year, the company posted $0.53 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis.
A number of analysts have recently weighed in on RMD shares. Analysts at Zacks upgraded shares of ResMed (NYSE:RMD) from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $55.40 price target on the stock. Separately, analysts at UBS AG downgraded shares of ResMed (NYSE:RMD) from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday. They now have a $50.50 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Goldman Sachs Group Inc. upgraded shares of ResMed (NYSE:RMD) to a “buy” rating in a research note to investors on Monday, September 23rd. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $48.41.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.